Daniel Pfeffer, Director of Oligonucleotide Production at Bachem shares why CDMO innovation is key to advancing next-generation oligonucleotide therapies.
Martin Kühn, managing director, and David Kötterheinrich, head of marketing at ERWEKA shares how pharmaceutical quality control and research laboratories, dissolution testing remains one of the most critical, and regulated, analytical processes.
Verista explores how shifting to “governance as code,” starting with practical automation of core controls, adopting risk-based AI classification, and cultivating a new generation of governance specialists can help organisations close that gap.
Mark Woolf, chief operating officer, COREX After 14 years of managing pharma logistics exclusively in CIS and Eastern European markets, Mark Woolf, COO of COREX, has seen the same misconceptions trip up Western pharma companies time and again.
John Donahue, vice president of sales, Scientific Safety Alliance discusses how a single contaminated batch triggers a chain of events that manufacturing teams may spend weeks, sometimes months, unraveling.
Ryan Crompton, laboratory manager at Broughton, outlines how QC release outputs must be interpreted in the context of stability expectations, degradation risks and evolving regulatory requirements.
After Pharmapack 2026, Olivia Friett spoke to Orhan Caglayan, executive vice president of the Pharma Portfolio, Informa, about the key takeaways from the event.
